Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or other checkpoint inhibitor antibodies.
Immunomedics, Inc.
C A C C A A C C C A A A C A C C C C C C A A A C A C C C A C C A C A A C A
C07K A61K C07K C07K A61K A61K C07K C07K C07K A61P A61K A61P C07K A61K C07K C07K C07K C07K C07K C07K A61K A61K A61K C07K A61K C07K C07K C07K A61K C07K C07K A61K C07K A61K A61K C07K A61K
inventional inventional additional additional inventional additional inventional additional inventional inventional additional inventional inventional inventional additional additional additional additional additional additional inventional inventional inventional inventional additional inventional additional inventional inventional additional inventional inventional inventional inventional inventional additional inventional
David M. Chien-Hsing
Goldenberg Chang